StockData
Lifeward Ltd. logo

Lifeward Ltd. (LFWD) company profile

LFWDNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 10/3066% below fair value
$4.06−1.66 (-29.02%)

Close on Nov 13, 2026Market cap $11.50MP/E –Yield –

About Lifeward

Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842

Lifeward Ltd. develops, manufactures, and markets medical devices and robotic systems designed for physical rehabilitation, recovery, and mobility. Its product portfolio includes ReWalk Personal and Rehabilitation powered exoskeletons for individuals with spinal cord injuries and paraplegia, AlterG Anti-Gravity Systems for physical therapy and athletic training, and MyoCycle functional electrical stimulation cycles. The company also offers extended warranties, product leasing, maintenance services, and related consumable accessories. Its target customers comprise rehabilitation clinics, physical therapy centers, healthcare facilities, and individual end-users requiring personal mobility assistance.

The company operates internationally, serving customers across the United States, Europe, the Asia-Pacific region, and other global markets. Lifeward conducts development, quality management, and ReWalk product manufacturing in Israel, while utilizing third-party contract manufacturing for its AlterG products. The company maintains its principal executive offices in Hudson, Massachusetts, United States.

Summary of the business section of Lifeward's latest annual report, written by StockData.

Company profile

Company

Legal name
Lifeward Ltd.
Founded
2001
Headquarters
Hudson, MA
Address
2 Cabot Road 01749
Phone
15082511154
Employees
81, Dec 31, 2025
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Incorporated in
L3
Fiscal year ends
December 31
Auditor
KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel

Stock & identifiers

Ticker
LFWD
Former tickers
RWLK until Jan 30, 2024
Exchange
Nasdaq
IPO date
Sep 12, 2014
Shares outstanding
3M, Aug 12, 2026
Public float
$9.97M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-12 reverse, Feb 24, 2026; 1-for-7 reverse, Mar 15, 2024; 1-for-25 reverse, Apr 1, 2019
SEC CIK
1607962
CUSIP
M8216Q309
FIGI
BBG006SYKFN0
Share class FIGI
BBG006SYKFP8
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William Mark GrantPresident & CEO, Director–
Lawrence J. JasinskiChief Executive Officer, Director100,870
Ronen TsimermanChief Financial Officer–
Keith Dale RoseChief Medical Officer17,083
Almog AdarChief Financial Officer262,500
Jeannine LynchVP of Market Access & Strategy142,134
Ariel KallnerDirector–
Haggai ZamirDirector6,711
Yonason GreenwaldDirector6,711
Avraham GabayDirector13,643
Moshe H. RozenbaumDirector11,485
William Mark SigsbeeDirector11,485
Yehuda ReznickDirector7,657
Nadav KidronDirector7,657
Miriam KidronDirector7,657
John William Poduska SrDirector55,953
Randel RichnerDirector57,487
Robert J. Marshall Jr.Director35,920
Joseph E. Turk JrDirector104,973
Hadar LevyDirector51,576
Michael SwinfordDirector100,960

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Non Principal Executive Officer And Non Executive Officer
$437.86K$393.15K$437.86K$11–
FY2025
PEOTwo
$834.87K$620.78K$437.86K$11–
FY2025
Principal Executive Officer
$798.20K$755.03K$437.86K$11–
FY2024
Non Principal Executive Officer And Non Executive Officer
$367.00K$254.09K$367.00K$33–
FY2024
PEOTwo
$0$0$367.00K$33–
FY2024
Principal Executive Officer
$473.27K$278.82K$367.00K$33–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Mark Grant
Former President and Chief Executive Officer
$253.75K$177.63K–$403.49K––$834.87K–
Larry Jasinski
Former Chief Executive Officer
$221.16K––––$577.05K$798.20K+69%
Almog Adar
Chief Financial Officer
$277.08K$40.00K–$133.24K$22.05K–$472.38K+67%
Jeannine Lynch
Former Vice President of Market Access and Strategy
$361.64K–$35.38K–$6.33K–$403.34K+12%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 81 employees (including full-time and”

Corporate history

Events identified from SEC filings

DateEventDetails
May 15, 2026Late filingNotification of late filing
Mar 25, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Mar 20, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 9, 2026Merger voteDefinitive merger proxy statement
Aug 8, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 16, 2024Name changeName changed from ReWalk Robotics Ltd. to Lifeward Ltd.
Oct 12, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 11, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 14, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 27, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 1, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 23, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 23, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 15, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 13, 2017Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 20, 2016Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 2, 2014ListingRegistration of securities on an exchange (Form 8-A)
May 16, 2014Name changeName changed from Argo Medical Technologies Ltd. to ReWalk Robotics Ltd.

See a number that looks wrong?